Literature DB >> 24457606

Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study.

Niels Steinebrunner1, Catharina Sandig1, Claudia Sommerer2, Ulf Hinz3, Thomas Giese4, Wolfgang Stremmel1, Alexandra Zahn1.   

Abstract

BACKGROUND: Due to considerable pharmacokinetic (PK) variability, immunosuppression with calcineurin inhibitors (CNIs) remains challenging. The objective of this study was to assess a pharmacodynamic (PD) approach of monitoring nuclear factor of activated T cell (NFAT)-regulated gene expression in the course of time and in correlation with rejection episodes. MATERIAL/
METHODS: 22 de novo liver allograft recipients were observed for a period of up to 12 months and the residual gene expression (RGE) of NFAT-regulated genes was monitored prospectively and correlated to acute rejection episodes.
RESULTS: There was a significant increase in RGEs between the time points 4-7 months and 1 month (25±7 µg/l vs. 9±5 µg/l, p≤0.0001) and 8-12 months and 1 month (50±8 µg/l vs. 10±7 µg/l, p=0.002) in the cyclosporine A (CsA) group, whereas in the tacrolimus (Tac) group a significant increase in RGEs appeared at the time point 8-12 months first. Acute rejection episodes occurred in 4 patients within 1 month after transplantation. These patients demonstrated a higher RGE of all NFAT-regulated genes compared to the other patients (CsA-treated patients: 39±0% vs. 11±5%, p=0.0001, Tac-treated patients: 48±12% vs. 18±10%, p=0.0082).
CONCLUSIONS: RGE of all NFAT-regulated genes show a relation between acute rejection episodes in the early post transplant period. Thus, this PD method has the potential to aid therapeutic drug monitoring.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24457606     DOI: 10.12659/AOT.889809

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  9 in total

1.  Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.

Authors:  Niels Steinebrunner; Wolfgang Stremmel; Karl H Weiss
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

2.  NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation.

Authors:  Sara Bremer; Nils T Vethe; Morten Skauby; Margrete Kasbo; Elisabet D Johansson; Karsten Midtvedt; Stein Bergan
Journal:  Br J Clin Pharmacol       Date:  2017-08-16       Impact factor: 4.335

Review 3.  A Rationale for Age-Adapted Immunosuppression in Organ Transplantation.

Authors:  Felix Krenzien; Abdallah ElKhal; Markus Quante; Hector Rodriguez Cetina Biefer; Uehara Hirofumi; Steven Gabardi; Stefan G Tullius
Journal:  Transplantation       Date:  2015-11       Impact factor: 4.939

4.  Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma.

Authors:  Fei Chen; Chuming Fan; Xuezhong Gu; Haixi Zhang; Qian Liu; Xiaoli Gao; Jie Lu; Baoli He; Xun Lai
Journal:  Med Sci Monit       Date:  2015-07-21

5.  Differential T Cell Signaling Pathway Activation by Tacrolimus and Belatacept after Kidney Transplantation: Post Hoc Analysis of a Randomised-Controlled Trial.

Authors:  Nynke M Kannegieter; Dennis A Hesselink; Marjolein Dieterich; Gretchen N de Graav; Rens Kraaijeveld; Carla C Baan
Journal:  Sci Rep       Date:  2017-11-09       Impact factor: 4.379

6.  Inhibition of nuclear factor of activated T cells (NFAT) c3 activation attenuates acute lung injury and pulmonary edema in murine models of sepsis.

Authors:  Manjula Karpurapu; Yong Gyu Lee; Ziqing Qian; Jin Wen; Megan N Ballinger; Luiza Rusu; Sangwoon Chung; Jing Deng; Feng Qian; Brenda F Reader; Teja Srinivas Nirujogi; Gye Young Park; Dehua Pei; John W Christman
Journal:  Oncotarget       Date:  2018-01-25

7.  Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.

Authors:  Niels Steinebrunner; Kerstin Stein; Catharina Sandig; Thomas Bruckner; Wolfgang Stremmel; Anita Pathil
Journal:  World J Gastroenterol       Date:  2018-02-21       Impact factor: 5.742

Review 8.  Pharmacokinetic and Pharmacodynamic Considerations in Relation to Calcineurin Usage in Elderly Kidney Transplant Recipients.

Authors:  Amelia R Cossart; Nicole M Isbel; Carla Scuderi; Scott B Campbell; Christine E Staatz
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

9.  The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.

Authors:  Claudia Sommerer; Matthias Schaier; Christian Morath; Vedat Schwenger; Geraldine Rauch; Thomas Giese; Martin Zeier
Journal:  Trials       Date:  2014-12-13       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.